Status:
UNKNOWN
Cilostazol and Endothelial Progenitor Cell
Lead Sponsor:
Gyeongsang National University Hospital
Collaborating Sponsors:
Korea Otsuka Pharmaceutical Co., Ltd.
Conditions:
Myocardial Infarction, Acute
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count...
Detailed Description
Primary endpoint: % Change of EPC count Secondary endpoints: 1. Changes of ADP/AA/collagen-induced PFT 2. Changes of lipid profile and high sensitivity-C-reactive protein 3. Change of TEG measuremen...
Eligibility Criteria
Inclusion
- naïve AMI
- undergoing successful coronary stent implantation
Exclusion
- high-risk patients for thrombotic event;
- a history of active bleeding or bleeding diatheses;
- contraindication to antiplatelet therapy;
- hemodynamic or electrical instability;
- oral anticoagulation therapy;
- left ventricular ejection fraction \< 30%;
- leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3;
- AST or ALT \> 3 times the respective the upper limit;
- serum creatinine level \> 3.5 mg/dL;
- stroke within 3 months;
- pregnancy;
- non-cardiac disease with a life expectancy \< 1 year;
- any patients not tolerable or suitable for coronary intervention; and
- inability to follow the protocol
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04407312
Start Date
January 1 2016
End Date
July 31 2020
Last Update
May 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.